Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Treat-and-Extend for CRVO-Related Macular Edema
jRCTs031180355Completed
- Sponsor
- Bayer
- Start
- Apr 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in central retinal vein occlusion (CRVO), sponsored by Bayer. Primary endpoint: Change in BCVA at Week 24. Started Apr 2018; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on jRCTs031180355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180355.